Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: The SALIR-E Study

Amedeo Capetti, Paola Meraviglia, Simona Landonio, Gaetana Sterrantino, Antonio Di Biagio, Sergio Lo Caputo, Adriana Ammassari, Barbara Menzaghi, Giuseppe Vittorio De Socio, Marco Franzetti, Alessandro Soria, Marianna Meschiari, Lolita Sasset, Giovanni Pellicanò, Elena Mazzotta, Michele Trezzi, Benedetto Maurizio Celesia, Sara Melzi, Laura Carenzi, Elena RicciGiuliano Rizzardini

Research output: Contribution to journalArticle

Abstract

Apart from the BENCHMRK study, there are no large observational experiences describing the long-term efficacy and safety of rescue regimens for human immunodeficiency virus type 1 (HIV-1) infection. Antiretroviral-experienced patients with detectable viraemia starting a raltegravir (RAL)-based regimen between March 2007 and June 2009 were consecutively enrolled and followed for ≥4 years. Data were censored at Week 206 for homogeneity. Of 333 patients, 258 (77.5%) were still on RAL-based therapy at Week 206, and 241 had undetectable HIV-1 RNA (73% in intention-to-treat analysis). Of the 75 subjects who discontinued RAL therapy, 36 were lost to follow-up, 15 changed their regimen due to virological failure, 2 simplified their regimen stopping RAL, 9 stopped all antiretrovirals and 13 died. Overall, 100 subjects (30.0%) had at least one detectable viraemia, but only 32 (9.6%) had true viral failure. Seventeen patients continued their failing regimen. 'Blips' were experienced by 53 patients (15.9%), whilst 15 (4.5%) had confirmed viral rebound due to adherence issues and were re-suppressed upon treatment re-introduction. In a multivariate analysis of predictors of interruption or failure, each baseline HIV-1 RNA log10 increase was associated with an adjusted hazard ratio for failure of 1.6; having more than 13 previous treatment courses also emerged as a predictor. Overall, adverse events were rare (n = 64), with 13 deaths. Tumours were mainly early events, often fatal (7/15), mainly non-Hodgkin's lymphomas (8), followed by hepatocarcinoma (2). RAL proved effective and well tolerated in this cohort, and few patients experienced viral failure after 4 years.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume43
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Salvage Therapy
HIV-1
Viremia
RNA
Therapeutics
Intention to Treat Analysis
Lost to Follow-Up
Virus Diseases
Non-Hodgkin's Lymphoma
Multivariate Analysis
Raltegravir Potassium
Safety
Neoplasms

Keywords

  • Experienced
  • HIV
  • Raltegravir
  • Resistance
  • Salvage

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients : The SALIR-E Study. / Capetti, Amedeo; Meraviglia, Paola; Landonio, Simona; Sterrantino, Gaetana; Di Biagio, Antonio; Lo Caputo, Sergio; Ammassari, Adriana; Menzaghi, Barbara; De Socio, Giuseppe Vittorio; Franzetti, Marco; Soria, Alessandro; Meschiari, Marianna; Sasset, Lolita; Pellicanò, Giovanni; Mazzotta, Elena; Trezzi, Michele; Celesia, Benedetto Maurizio; Melzi, Sara; Carenzi, Laura; Ricci, Elena; Rizzardini, Giuliano.

In: International Journal of Antimicrobial Agents, Vol. 43, No. 2, 02.2014, p. 189-194.

Research output: Contribution to journalArticle

Capetti, A, Meraviglia, P, Landonio, S, Sterrantino, G, Di Biagio, A, Lo Caputo, S, Ammassari, A, Menzaghi, B, De Socio, GV, Franzetti, M, Soria, A, Meschiari, M, Sasset, L, Pellicanò, G, Mazzotta, E, Trezzi, M, Celesia, BM, Melzi, S, Carenzi, L, Ricci, E & Rizzardini, G 2014, 'Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: The SALIR-E Study', International Journal of Antimicrobial Agents, vol. 43, no. 2, pp. 189-194. https://doi.org/10.1016/j.ijantimicag.2013.10.013
Capetti, Amedeo ; Meraviglia, Paola ; Landonio, Simona ; Sterrantino, Gaetana ; Di Biagio, Antonio ; Lo Caputo, Sergio ; Ammassari, Adriana ; Menzaghi, Barbara ; De Socio, Giuseppe Vittorio ; Franzetti, Marco ; Soria, Alessandro ; Meschiari, Marianna ; Sasset, Lolita ; Pellicanò, Giovanni ; Mazzotta, Elena ; Trezzi, Michele ; Celesia, Benedetto Maurizio ; Melzi, Sara ; Carenzi, Laura ; Ricci, Elena ; Rizzardini, Giuliano. / Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients : The SALIR-E Study. In: International Journal of Antimicrobial Agents. 2014 ; Vol. 43, No. 2. pp. 189-194.
@article{28fa8887e7ed47a4b427d2d5207c0e7f,
title = "Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: The SALIR-E Study",
abstract = "Apart from the BENCHMRK study, there are no large observational experiences describing the long-term efficacy and safety of rescue regimens for human immunodeficiency virus type 1 (HIV-1) infection. Antiretroviral-experienced patients with detectable viraemia starting a raltegravir (RAL)-based regimen between March 2007 and June 2009 were consecutively enrolled and followed for ≥4 years. Data were censored at Week 206 for homogeneity. Of 333 patients, 258 (77.5{\%}) were still on RAL-based therapy at Week 206, and 241 had undetectable HIV-1 RNA (73{\%} in intention-to-treat analysis). Of the 75 subjects who discontinued RAL therapy, 36 were lost to follow-up, 15 changed their regimen due to virological failure, 2 simplified their regimen stopping RAL, 9 stopped all antiretrovirals and 13 died. Overall, 100 subjects (30.0{\%}) had at least one detectable viraemia, but only 32 (9.6{\%}) had true viral failure. Seventeen patients continued their failing regimen. 'Blips' were experienced by 53 patients (15.9{\%}), whilst 15 (4.5{\%}) had confirmed viral rebound due to adherence issues and were re-suppressed upon treatment re-introduction. In a multivariate analysis of predictors of interruption or failure, each baseline HIV-1 RNA log10 increase was associated with an adjusted hazard ratio for failure of 1.6; having more than 13 previous treatment courses also emerged as a predictor. Overall, adverse events were rare (n = 64), with 13 deaths. Tumours were mainly early events, often fatal (7/15), mainly non-Hodgkin's lymphomas (8), followed by hepatocarcinoma (2). RAL proved effective and well tolerated in this cohort, and few patients experienced viral failure after 4 years.",
keywords = "Experienced, HIV, Raltegravir, Resistance, Salvage",
author = "Amedeo Capetti and Paola Meraviglia and Simona Landonio and Gaetana Sterrantino and {Di Biagio}, Antonio and {Lo Caputo}, Sergio and Adriana Ammassari and Barbara Menzaghi and {De Socio}, {Giuseppe Vittorio} and Marco Franzetti and Alessandro Soria and Marianna Meschiari and Lolita Sasset and Giovanni Pellican{\`o} and Elena Mazzotta and Michele Trezzi and Celesia, {Benedetto Maurizio} and Sara Melzi and Laura Carenzi and Elena Ricci and Giuliano Rizzardini",
year = "2014",
month = "2",
doi = "10.1016/j.ijantimicag.2013.10.013",
language = "English",
volume = "43",
pages = "189--194",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients

T2 - The SALIR-E Study

AU - Capetti, Amedeo

AU - Meraviglia, Paola

AU - Landonio, Simona

AU - Sterrantino, Gaetana

AU - Di Biagio, Antonio

AU - Lo Caputo, Sergio

AU - Ammassari, Adriana

AU - Menzaghi, Barbara

AU - De Socio, Giuseppe Vittorio

AU - Franzetti, Marco

AU - Soria, Alessandro

AU - Meschiari, Marianna

AU - Sasset, Lolita

AU - Pellicanò, Giovanni

AU - Mazzotta, Elena

AU - Trezzi, Michele

AU - Celesia, Benedetto Maurizio

AU - Melzi, Sara

AU - Carenzi, Laura

AU - Ricci, Elena

AU - Rizzardini, Giuliano

PY - 2014/2

Y1 - 2014/2

N2 - Apart from the BENCHMRK study, there are no large observational experiences describing the long-term efficacy and safety of rescue regimens for human immunodeficiency virus type 1 (HIV-1) infection. Antiretroviral-experienced patients with detectable viraemia starting a raltegravir (RAL)-based regimen between March 2007 and June 2009 were consecutively enrolled and followed for ≥4 years. Data were censored at Week 206 for homogeneity. Of 333 patients, 258 (77.5%) were still on RAL-based therapy at Week 206, and 241 had undetectable HIV-1 RNA (73% in intention-to-treat analysis). Of the 75 subjects who discontinued RAL therapy, 36 were lost to follow-up, 15 changed their regimen due to virological failure, 2 simplified their regimen stopping RAL, 9 stopped all antiretrovirals and 13 died. Overall, 100 subjects (30.0%) had at least one detectable viraemia, but only 32 (9.6%) had true viral failure. Seventeen patients continued their failing regimen. 'Blips' were experienced by 53 patients (15.9%), whilst 15 (4.5%) had confirmed viral rebound due to adherence issues and were re-suppressed upon treatment re-introduction. In a multivariate analysis of predictors of interruption or failure, each baseline HIV-1 RNA log10 increase was associated with an adjusted hazard ratio for failure of 1.6; having more than 13 previous treatment courses also emerged as a predictor. Overall, adverse events were rare (n = 64), with 13 deaths. Tumours were mainly early events, often fatal (7/15), mainly non-Hodgkin's lymphomas (8), followed by hepatocarcinoma (2). RAL proved effective and well tolerated in this cohort, and few patients experienced viral failure after 4 years.

AB - Apart from the BENCHMRK study, there are no large observational experiences describing the long-term efficacy and safety of rescue regimens for human immunodeficiency virus type 1 (HIV-1) infection. Antiretroviral-experienced patients with detectable viraemia starting a raltegravir (RAL)-based regimen between March 2007 and June 2009 were consecutively enrolled and followed for ≥4 years. Data were censored at Week 206 for homogeneity. Of 333 patients, 258 (77.5%) were still on RAL-based therapy at Week 206, and 241 had undetectable HIV-1 RNA (73% in intention-to-treat analysis). Of the 75 subjects who discontinued RAL therapy, 36 were lost to follow-up, 15 changed their regimen due to virological failure, 2 simplified their regimen stopping RAL, 9 stopped all antiretrovirals and 13 died. Overall, 100 subjects (30.0%) had at least one detectable viraemia, but only 32 (9.6%) had true viral failure. Seventeen patients continued their failing regimen. 'Blips' were experienced by 53 patients (15.9%), whilst 15 (4.5%) had confirmed viral rebound due to adherence issues and were re-suppressed upon treatment re-introduction. In a multivariate analysis of predictors of interruption or failure, each baseline HIV-1 RNA log10 increase was associated with an adjusted hazard ratio for failure of 1.6; having more than 13 previous treatment courses also emerged as a predictor. Overall, adverse events were rare (n = 64), with 13 deaths. Tumours were mainly early events, often fatal (7/15), mainly non-Hodgkin's lymphomas (8), followed by hepatocarcinoma (2). RAL proved effective and well tolerated in this cohort, and few patients experienced viral failure after 4 years.

KW - Experienced

KW - HIV

KW - Raltegravir

KW - Resistance

KW - Salvage

UR - http://www.scopus.com/inward/record.url?scp=84893691010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893691010&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2013.10.013

DO - 10.1016/j.ijantimicag.2013.10.013

M3 - Article

C2 - 24315315

AN - SCOPUS:84893691010

VL - 43

SP - 189

EP - 194

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -